Generic Name and Formulations:
Anthralin 1%; crm, contains salicylic and ascorbic acid.
Indications for DRITHO-CREME:
Quiescent or chronic psoriasis.
Initially apply once daily (5–10 minutes contact time) for at least one week; may increase contact time to 20–30 minutes before washing off. Treat until skin is entirely clear. Individualize. For skin: use sparingly. For scalp: wash and rinse hair.
Acute psoriatic eruptions.
Renal disease. Avoid eyes, mucous membranes, folds and creases of the skin. Apply cautiously on intertriginous skin areas. Restrict application to psoriatic lesions. Discontinue if sensitization or excessive irritation develops. May stain fabrics; avoid. Pregnancy (Cat.C). Nursing mothers.
Possible contact allergic reactions, severe irritation, discolored hair or fingernails.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|